Metabolic tumor volume predicts outcome in advanced stage follicular lymphoma patients from the Relevance trial.

Fiche publication

Date publication

octobre 2023

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier , Pr FEUGIER Pierre

Tous les auteurs :
Cottereau AS, Rebaud L, Trotman J, Feugier P, Nastoupil LJ, Bachy E, Flinn IW, Haioun C, Ysebaert L, Bartlett NL, Tilly H, Casasnovas O, Ricci R, Portugues C, Buvat I, Meignan M, Morschhauser F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37898239

Résumé

We investigated the prognostic value of baseline PET parameters for patients with treatment-naïve follicular lymphoma (FL) in the phase 3 RELEVANCE trial, comparing the immunomodulatory combination of lenalidomide and rituximab (R) vs R-chemotherapy (R-chemo), with both regimens followed by R maintenance therapy.